In the long human effort to understand why the body turns against itself, a team of South Korean researchers has taken a significant step forward — merging the vast scale of genomic population data with the intimate resolution of single-cell biology to trace psoriasis from inherited risk to cellular malfunction. Published in Nature Communications, the work led by Hong-Hee Won at Sungkyunkwan University identifies 125 genetic sites linked to psoriasis onset, 17 of them previously unknown, and points toward 50 potential targets for treatment. For the roughly 2% of humanity living with this autoi
South Korean researchers map psoriasis genetic code using big data and single-cell analysis
Which genes matter are actually being used by which cells
Mark
So they looked at 1.1 million people's genetic data and also looked at cells under a microscope. Why was it important to do both?
Mimi
Because psoriasis had been studied two ways separately—geneticists would find variants linked to the disease, and cell biologists would study what happens in the skin—but nobody had really connected the dots. This team asked: which genes that we know matter are actually being used by which cells?
Luke
Fair enough. But when they say they identified 125 susceptibility loci, how confident are we in that number? Is that across all 1.1 million people, or is it a meta-analysis of existing studies?
Mimi
It's a meta-analysis—they combined data from multiple previous studies. So the 1.1 million is the total sample size across all those studies.
Mark
And the 17 new ones—how do we know they're actually new and not just missed before?
Mimi
They compared their findings to all previously published genetic studies of psoriasis. If a locus hadn't shown up in any of those, it's new to the literature.
Luke
That's a reasonable bar, though "new to the literature" is different from "definitely causes psoriasis." These are associations, right? They found genetic variants that are more common in people with psoriasis.
Mimi
Correct. The next step would be functional studies to understand what those variants actually do.
Mark
And the 50 therapeutic targets—are those genes they think drugs could target, or genes they've already tested drugs against?
Mimi
They identified them through screening as promising candidates. They haven't necessarily tested drugs yet. That's the next phase.
Luke
So this is a roadmap, not a finished product.
Mimi
Exactly. It's a very detailed roadmap, but the actual drug development work still lies ahead.
Le Pouls
- Psoriasis has long resisted full understanding because its genetic roots and its cellular behavior have been studied in isolation — this research forcibly closes that gap.
- By analyzing genomic data from over 1.1 million people alongside single-cell transcriptomics from actual skin tissue, the team caught the disease operating at two scales simultaneously.
- The cellular picture that emerged is one of miscommunication: immune cells and skin cells locked in a signaling loop that drives runaway inflammation.
- Seventeen genetic loci linked to psoriasis had never been identified before, expanding the map of susceptibility in ways that could reframe how the disease is diagnosed and targeted.
- Fifty genes now stand identified as potential intervention points — places where a future drug might break the inflammatory chain before it escalates.
- The trajectory points toward treatments tailored to individual patients rather than broad immunosuppression, a meaningful shift for a disease that currently offers no cure.
In the long human effort to understand why the body turns against itself, a team of South Korean researchers has taken a significant step forward — merging the vast scale of genomic population data with the intimate resolution of single-cell biology to trace psoriasis from inherited risk to cellular malfunction. Published in Nature Communications, the work led by Hong-Hee Won at Sungkyunkwan University identifies 125 genetic sites linked to psoriasis onset, 17 of them previously unknown, and points toward 50 potential targets for treatment. For the roughly 2% of humanity living with this autoimmune condition — and its cascading risks of arthritis, heart disease, and metabolic disorder — the findings suggest that personalized medicine may be moving from aspiration to architecture.
A South Korean research team has done something rarely attempted in the study of autoimmune disease: they brought together two powerful but previously separate scientific lenses — large-scale genomic analysis and single-cell biology — and trained them on psoriasis at the same time. Led by Hong-Hee Won at Sungkyunkwan University's Samsung Advanced Institute for Health Sciences and Technology, the study was published in Nature Communications and represents one of the most comprehensive mappings of psoriasis genetics to date.
Psoriasis is familiar on the surface — the red, scaly patches that affect roughly 2% of the global population — but its consequences run deeper. As an autoimmune condition, it elevates risk for arthritis, cardiovascular disease, obesity, and diabetes. Yet genetic research and cellular research into the disease have largely proceeded on separate tracks, leaving a gap between knowing which genes are implicated and understanding what those genes actually do inside living tissue.
Won's team bridged that gap through a meta-analysis of genomic data from more than 1.1 million individuals, surfacing 125 genetic susceptibility loci — 17 of which had never been reported before. They then turned to skin samples from both healthy individuals and psoriasis patients, using single-cell transcriptomics to observe gene activity at the level of individual cells. What they found was a breakdown in cellular communication: immune cells — myeloid cells and T cells — were sending signals that triggered excessive inflammation in skin keratinocytes and blood vessel cells, creating a self-reinforcing cascade.
From this picture, the researchers identified 50 genes as potential therapeutic targets — specific points where a drug might interrupt the inflammatory process. Won described the findings as a foundation for personalized immune-modulating treatments, moving medicine away from broad interventions and toward therapies designed around individual patients. The work reframes psoriasis not as a genetic problem or a cellular problem, but as both at once — a disease born from the collision between inherited susceptibility and the behavior of specific cells in the skin.
A team of South Korean researchers has mapped the genetic architecture of psoriasis by merging two powerful but previously separate scientific approaches: analysis of genomic data from more than 1.1 million people and examination of individual cell behavior in skin tissue. The work, led by Hong-Hee Won at Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University and Samsung Medical Center, with Hyeonbin Jo as first author, was published in Nature Communications and identifies 125 genetic sites linked to the disease's onset—17 of them entirely new to science.
Psoriasis affects roughly 2% of the world's population, manifesting as the red, scaly patches most people recognize. But the disease runs far deeper than skin. It is fundamentally an autoimmune condition in which the body's own immune system attacks its tissue, and it carries serious downstream consequences: people with psoriasis face elevated risk of arthritis, cardiovascular disease, obesity, and diabetes. Until now, genetic studies and cellular-level investigations of the disease have largely proceeded on separate tracks. Few researchers had attempted to stitch together large-scale genetic findings with the actual behavior of cells in living tissue to trace a clear path from genetic susceptibility to disease.
Won's team closed that gap through an integrated approach. They conducted a meta-analysis of genomic data spanning more than 1.1 million individuals, identifying 125 genetic susceptibility loci—specific locations in the genome where variations increase psoriasis risk. Seventeen of these loci had never been reported before. The team then moved to skin samples, using single-cell transcriptomic analysis to observe which genes were active in individual cells from both healthy people and psoriasis patients. This allowed them to see not just which genes mattered, but which cells were actually using them.
What emerged was a picture of cellular choreography gone wrong. Myeloid cells and T cells from the immune system were interacting with keratinocytes on the skin's surface and vascular endothelial cells in blood vessels. These interactions triggered a cascade of molecular signals that drove excessive inflammation. By mapping how these different cell types communicated across the various layers of skin, the researchers identified 50 genes that could serve as targets for new treatments—points where a drug might interrupt the inflammatory chain reaction.
Won framed the significance plainly: the research reveals which genetic factors and cell types are actually responsible for psoriasis pathology. The findings, he suggested, could become a foundation for developing personalized immune-modulating treatments and drugs designed for individual patients rather than a one-size-fits-all approach. The work represents a shift from understanding psoriasis as either a genetic problem or a cellular problem toward seeing it as both simultaneously—a disease that emerges from the interaction between inherited susceptibility and the behavior of specific cell populations in the skin.
Citations marquantes
This research combines large-scale genomic data with precise cellular transcriptomic analysis to clearly reveal which genetic factors and cell types are involved in psoriasis pathology.— Hong-Hee Won, lead researcher
Envie de l'histoire complète ?
Lire l'original sur Medical Xpress ↗
Health & Medicine